-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, EII055N8yQUwK5NonvMyR//XUuVujnQ2WCGRX7NXNbuSPn2CSdMKoHM29kAr0bF3 NMXJdkAZbvHZtFUWBOq1Xg== 0001356018-07-000333.txt : 20070726 0001356018-07-000333.hdr.sgml : 20070726 20070726135902 ACCESSION NUMBER: 0001356018-07-000333 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070725 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Other Events FILED AS OF DATE: 20070726 DATE AS OF CHANGE: 20070726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AOB BIOTECH INC CENTRAL INDEX KEY: 0001363449 STANDARD INDUSTRIAL CLASSIFICATION: STATE COMMERCIAL BANKS [6022] IRS NUMBER: 900110902 FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52221 FILM NUMBER: 071001989 BUSINESS ADDRESS: STREET 1: 301 N LAKE AVENUE STREET 2: SUITE 202 CITY: PASADENA STATE: CA ZIP: 91101 BUSINESS PHONE: 6267963988 MAIL ADDRESS: STREET 1: 301 N LAKE AVENUE STREET 2: SUITE 202 CITY: PASADENA STATE: CA ZIP: 91101 8-K 1 form8k.htm AOB FORM 8-K ITEMS 5.02 AND 8.01 form8k.htm
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 8-K

CURRENT REPORT
 
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
DATE OF REPORT (Date of earliest event reported): July 20, 2007


(Exact name of registrant as specified in its charter)



California
90-0110902
(State or other jurisdiction of incorporation or organization)
(IRS Employer Identification No.)


0-32923
(Commission File Number)


301 N. Lake Avenue, Suite 202
Pasadena, CA 91101
(626) 796-3988
(Address of principal executive offices)
(Registrant’s telephone number)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

q  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

q  
Soliciting material pursuant to Rule 14a-12 under the exchange Act (17 CFR 240.14a-12)

q  
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

q  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
 
 

 
Section 5.  Corporate Governance and Management

Item 5.02.  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

(a)  Effective July 20, 2007, Nelson Liao resigned as Chief Executive Officer, Secretary and Director of the Company.  The separation was amicable and the Company accepted Mr. Liao’s resignations. Mr. Liao was named in a Securities and Exchange Commission action which is described under “Item 8.01 Other Matters” below. The Company has not been named in the SEC action.

(b) Effective July 20, 2007, Dr. Eva Aw, currently President of the Company, was appointed to the position of Interim Chief Executive Officer. Ms. Haijing (Carrie) Wang, currently the Chief Financial Officer of the Company, was appointed Secretary of the Company.


Item 8.01.  Other Matters

In an action filed by the Securities and Exchange Commission (“SEC”) on July 12, 2007 the United District Court for the Central District of California issued a temporary restraining order against Mr. Liao and several companies he controls. The order halted an alleged securities offering, appointed a temporary receiver and froze the assets of Mr. Liao and the named companies. A hearing on whether a preliminary injunction should be issued and whether a permanent receiver should be appointed is scheduled for August 13, 2007.



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
AOB Biotech, Inc.
   
   
Date: July 25, 2007
/s/ Dr. Eva Aw
 
Dr. Eva Aw,
 
Interim Chief Executive Officer
 

 
 
- 2 -
 


 -----END PRIVACY-ENHANCED MESSAGE-----